Dr. Yoshino Discusses the Safety Profile of TAS-102
Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses the safety profile of TAS-102 as seen in a phase III study of the agent versus placebo, with best supportive care, in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.
Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses the safety profile of TAS-102 as seen in a phase III study of the agent versus placebo with best supportive care in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.
Yoshino says that TAS-102 is well tolerated overall with very mild toxicity. The most common adverse events observed in the TAS-102 arm were hematologic, including anemia (16.5%) and neutropenia (34.9%).
There were also some incidences of diarrhea, pyrexia and vomiting, Yoshino says, but these were generally manageable. Based on this, Yoshino says he believes that TAS-102 is very well tolerated in almost all patients.
<<<
%201%20(1)%20copy.jpg?fit=crop&auto=format)
